<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161692</url>
  </required_header>
  <id_info>
    <org_study_id>INT48/96</org_study_id>
    <nct_id>NCT02161692</nct_id>
  </id_info>
  <brief_title>Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors</brief_title>
  <official_title>Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of a sequential high dose
      chemotherapy is more effective than conventional dose (i.e. 4 cycles of cisplatin, etoposide,
      and bleomycin [PEB]) in patients with metastatic poor prognosis germ cell tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of disease progression confirmed by computed tomography (CT) scan and/or serum tumor markers.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Testicular Neoplasms</condition>
  <condition>Germ Cell Tumors</condition>
  <arm_group>
    <arm_group_label>High dose chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Characterized by the following sequence:
High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin
1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional dose chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>High dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>High dose chemotherapy</arm_group_label>
    <arm_group_label>Conventional dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>High dose chemotherapy</arm_group_label>
    <arm_group_label>Conventional dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <arm_group_label>Conventional dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>High dose carboplatin</description>
    <arm_group_label>High dose chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical or Histological diagnosis of germ cell tumors

          -  Metastatic disease

          -  Poor prognostic category according to the International Germ Cell Collaborative Group
             (IGCCCG) classification

          -  No prior chemotherapy for metastatic disease

        Exclusion Criteria:

          -  Unwillingness to accomplish the study procedures

          -  Any existing co-morbidity that could limit the administration of high dose
             chemotherapy

          -  Any psychiatric disorder that could impact on the study compliance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Necchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale dei Tumori, Milano Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.istitutotumori.mi.it/modules.php?name=Content&amp;pa=showpage&amp;pid=158</url>
    <description>Website of the Urology Unit, Istituto Nazionale dei Tumori, Milano Italy</description>
  </link>
  <reference>
    <citation>Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer J. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011 Jun 1;29(16):2178-84. doi: 10.1200/JCO.2010.32.6678. Epub 2011 Mar 28.</citation>
    <PMID>21444870</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>June 11, 2014</last_update_submitted>
  <last_update_submitted_qc>June 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Andrea Necchi</investigator_full_name>
    <investigator_title>Faculty, Department of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

